3 completed, 1 not yet recruiting, 1 suspended. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Not yet recruiting 1, Suspended 1 |
Follow 3M-052-AF: new trials by email Literature Review of 3M-052-AF trials Research Report on 3M-052-AF
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected 426c.Mod.Core-C4b, 3M-052-AF, Aluminum hydroxide suspension (Alum) - HIV Infections | Phase 1 | Not yet recruiting | HIV Vaccine Trials Network | 22 | 2027-03-30 | 2026-09-18 |
| Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension - HIV-1 | Phase 1 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2025-04-01 | 2026-03-03 |
| Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults VLA1601, CpG 1018®, 3M-052-AF - Zika, Zika Virus Infection | Phase 1 | Completed | Valneva Austria GmbH | 150 | 2024-03-25 | 2026-03-09 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV sD-NP-GT8 DNA, IL-12 DNA, Trimer 4571 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 46 | 2023-04-10 | 2025-11-14 |
| Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults BG505 SOSIP.664 gp140, Placebo, 3M-052-AF - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 127 | 2020-01-13 | 2025-09-02 |
HIV Infections (3) · Zika Virus Infection (1)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · HIV Vaccine Trials Network (1) · Valneva Austria GmbH (1)
United States (4) · South Africa (2)
Amy Violari (1) · M. Juliana McElrath (1) · Madhu Choudhary, MD (1) · Nadine Rouphael (1)
UM1AI068614 (1)